Bristol Myers Squibb CELG-RI
NYSE CELG-RI
$0.12 +0.02 (+17.65%)
As of: Aug 21, 2026 · 2:40 PM EDT

Bristol Myers Squibb (CELG-RI) Amortizatization of Intangibles (2009 - 2012)

Bristol Myers Squibb (CELG-RI) posted quarterly Amortizatization of Intangibles of $102.0 million for Q2 2012, up 7.37% year-over-year from $95.0 million in Q3 2011, and up 0.99% quarter-over-quarter from $101.0 million in Q1 2012.

Bristol Myers Squibb (CELG-RI) Amortizatization of Intangibles (2009 - 2012) Analysis & Trends

Bristol Myers Squibb (CELG-RI) has reported Amortizatization of Intangibles for 4 consecutive years, with $102.0 million the latest figure, recorded in Q2 2012.

  • In Q2 2012, Amortizatization of Intangibles rose 7.37% year-over-year to $102.0 million; the TTM figure through Jun 2012 stood at $388.0 million (up 26.38% YoY), while the FY2011 annual figure was $353.0 million, up 30.26% from the prior year.
  • Amortizatization of Intangibles grew to $102.0 million in Q2 2012 per CELG-RI's latest filing, from $101.0 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $102.0 million in Q2 2012 and bottomed at $59.0 million in Q3 2009.
  • Historically, Amortizatization of Intangibles has averaged $80.3 million across 4 years, with a median of $75.5 million in 2009.
  • Annual changes were most pronounced in 2010 — Amortizatization of Intangibles dropped 6.41% — and 2011, when it jumped 41.79%.
  • Bristol Myers Squibb's Amortizatization of Intangibles stood at $78.0 million in 2009, then decreased by 6.41% to $73.0 million in 2010, then increased by 26.03% to $92.0 million in 2011, then gained by 10.87% to $102.0 million in 2012.
  • Business Quant data shows CELG-RI's Amortizatization of Intangibles at $102.0 million in Q2 2012, $101.0 million in Q1 2012, and $92.0 million in Q4 2011.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn -
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn -
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn 984.00 Mn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn -
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn -
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn -
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn 600.00 Mn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn -
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn -
10 Bristol Myers Squibb 224.21 Mn -10.84 Bn 9.25 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2012 102.00 Mn
Jun 30, 2012 102.00 Mn
Mar 31, 2012 101.00 Mn
Mar 31, 2012 101.00 Mn
Dec 31, 2011 92.00 Mn
Dec 31, 2011 92.00 Mn
Sep 30, 2011 93.00 Mn
Sep 30, 2011 93.00 Mn
Jun 30, 2011 95.00 Mn
Jun 30, 2011 95.00 Mn
Mar 31, 2011 73.00 Mn
Mar 31, 2011 73.00 Mn
Dec 31, 2010 73.00 Mn
Dec 31, 2010 73.00 Mn
Sep 30, 2010 66.00 Mn
Sep 30, 2010 66.00 Mn
Jun 30, 2010 67.00 Mn
Jun 30, 2010 67.00 Mn
Mar 31, 2010 65.00 Mn
Mar 31, 2010 65.00 Mn